NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 10726.25 -19.80 -0.18%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM)

 
JAGSNPHARM Technical Analysis
4
As on 15th Feb 2019 JAGSNPHARM Share Price closed @ 28.00 and we RECOMMEND Sell for LONG-TERM with Stoploss of 28.29 & Strong Sell for SHORT-TERM with Stoploss of 30.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

JAGSNPHARM Share Price

Open 28.65 Change Price %
High 30.45 1 Day -1.50 -5.08
Low 27.40 1 Week -0.90 -3.11
Close 28.00 1 Month -2.95 -9.53
Volume 23103 1 Year -5.00 -15.15
52 Week High 34.95 | 52 Week Low 22.40
 
NSE INDIA Most Active Stocks
YESBANK 219.00 -1.02%
RCOM 5.50 -0.90%
ASHOKLEY 79.95 -5.33%
CGPOWER 29.30 1.56%
ONGC 135.00 2.16%
ITC 280.10 0.79%
GMRINFRA 14.85 0.34%
INFIBEAM 39.45 10.97%
RPOWER 10.20 -4.23%
IDEA 30.00 -5.21%
 
NSE INDIA Top Gainers Stocks
PRAKASHSTL 0.35 16.67%
JIKIND 0.35 16.67%
MSPL 13.35 15.09%
CYBERTECH 37.45 12.29%
PROSEED 0.50 11.11%
INFIBEAM 39.45 10.97%
TCIDEVELOP 386.55 10.44%
PRAENG 9.10 10.30%
NIBL 19.95 10.22%
BAGFILMS 4.90 10.11%
 
NSE INDIA Top Losers Stocks
MVL 0.20 -20.00%
MVL 0.20 -20.00%
MANAKCOAT 6.05 -17.69%
TECHNOFAB 89.55 -16.35%
SOMICONVEY 23.20 -15.33%
SHAHALLOYS 13.35 -14.42%
MADHUCON 5.25 -13.22%
TTL 50.20 -10.44%
NAHARINDUS 37.55 -10.06%
ANKITMETAL 0.45 -10.00%
 
 
JAGSNPHARM
Daily Charts
JAGSNPHARM
Intraday Charts
Whats New @
Bazaartrend
JAGSNPHARM
Free Analysis
 
JAGSNPHARM Important Levels Intraday
RESISTANCE33.88
RESISTANCE31.99
RESISTANCE30.83
RESISTANCE29.66
SUPPORT26.34
SUPPORT25.17
SUPPORT24.01
SUPPORT22.12
 
JAGSNPHARM Target for Month February
4th UP TARGET39.02
3rd UP TARGET36.61
2nd UP TARGET35.12
1st UP TARGET33.63
1st DOWN TARGET29.37
2nd DOWN TARGET27.88
3rd DOWN TARGET26.39
4th DOWN TARGET23.98
 
JAGSNPHARM Weekly Target
4th UP TARGET35.74
3rd UP TARGET33.55
2nd UP TARGET32.19
1st UP TARGET30.83
1st DOWN TARGET26.97
2nd DOWN TARGET25.61
3rd DOWN TARGET24.25
4th DOWN TARGET22.06
 
JAGSNPHARM Target for Year 2019
4th UP TARGET78.51
3rd UP TARGET63.37
2nd UP TARGET54.01
1st UP TARGET44.65
1st DOWN TARGET17.95
2nd DOWN TARGET8.59
3rd DOWN TARGET-0.77
4th DOWN TARGET-15.91
 
Jagsonpal Pharmaceuticals Limited ( NSE INDIA Symbol : JAGSNPHARM )
Sector : Pharmaceuticals - Formulations And Other Stocks in Same Sector
 
JAGSNPHARM Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 46.04 Sideways
MFI (14) MFI is 57.19 Sideways
CCI (20) CCI is -69.04 Sideways
WILLIAM %R (14) William %R is -58.25 Sideways
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Long Buy 27.35
10 Day Avg Volume Traded 177.17 % More then 10 Day Average Volume
 
JAGSNPHARM Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals - Formulations
Industry
Offical website
 
JAGSNPHARM Address
JAGSNPHARM
N/A
 
JAGSNPHARM Latest News
 
Your Comments and Response on Jagsonpal Pharmaceuticals Limited
 
JAGSNPHARM Business Profile
Jagson Pharma is in the Pharmaceuticals - Formulations sector. Jagsonpal Pharmaceuticals (JAGSONPH) is a pharmaceutical company producing drugs and formulations. The company was incorporated in 1978 as a private limited company and went public in 1986. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. It focuses on several therapeutic groups like anti-arthritics, anti-inflammatories, analgesics, anti-spasmodics, progesterones, anabolic steroids, anesthetics and anti-fungals. Top selling brands include Lycored, Maintane, Metadec, Metabol, Doxypal DR, Parvon, and Indocap SR. The company manufactures active pharmaceutical ingredients (APIs) like Allylestrenol, Disulfiram, Tolnaftate, ..etc. The bulk drug range includes dextropropoxyphene HCl, tolnaftate, dextropropoxyphene napsylate and thiopental sodium. The manufacturing facility in Delhi is WHO and GMP-certified for the production of various dosage forms and bulk drugs and intermediates. The company also maintains a number of dedicated contract manufacturing facilities around the globe. It has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe. The distribution network in India is comprised of over 1,500 authorized stockists who are serviced by depots. The products are retailed at over 125,000 pharmacies. The company is represented by 2,500 agents worldwide and has offices in three continents. The company`s operations span Russia, USA, Brazil, Ukraine, Sri Lanka, Cameroon, Argentina, Thailand, Germany, Switzerland, Korea, Egypt and Vietnam. The company has a sales office in New York through which it services North and Latin American clients and in Belarus, it has an operation center with a sales and distribution team. The current market capitalisation stands at Rs 23.71 crore.The company has reported a standalone sales of Rs 36.79 crore and a Net Profit of Rs 0.01 crore for the quarter ended Sep 2013. The company management includes R P S Kochhar - Chairman & Managing Director, S K Goyal - Director, Govind Deo - Additional Director, Bharat Sinh - Additional Director, Ishpal Singh Ghai - Additional Director. It is listed on the BSE with a BSE Code of 507789 and the NSE with an NSE Code of JAGSNPHARM. Its Registered office is at T-210 J, Shahpur Jat , New Delhi,Delhi - 110049.
 
2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service